LUPIN LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,660 INR | 0.00% |
|
+3.11% | +25.46% |
| 10:36am | Lupin Gets Six Observations from US FDA After Somerset Unit Inspection | MT |
| 13/05 | Lupin Relaunches Mirabegron ER Tablets in US | MT |
Presentation Operator MessageOperator (Operator)Welcome to Lupin Limited Q3 FY 2023 Earnings C...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas:
- design and production of generic and brand-name formulations;
- production of active pharmaceutical ingredients.
At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil.
Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).
Sector
Pharmaceuticals
Calendar
07/08/2024
- Q1 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
HOLD
Number of Analysts
35
Last Close Price
1,660
INR
Average target price
1,567
INR
Spread / Average Target
-5.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.46% | 9.08B | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +13.66% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- LUPIN Stock
- News Lupin Limited
- Transcript : Lupin Limited, Q3 2023 Earnings Call, Feb 10, 2023
